<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401735</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBHPAIN</org_study_id>
    <nct_id>NCT04401735</nct_id>
  </id_info>
  <brief_title>Effects and Safety of Epidural PDRN vs. Placebo</brief_title>
  <official_title>Effects and Safety of PDRN (Polydeoxyribonucleotide) for Patient With Lumbar Spinal Stenosis Compared With Normal Saline in Randomized Placebo-Controlled Comparative Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, double-blind clinical study to assess the clinical
      application and outcomes with epidural PDRN versus Normal saline injection in patients with
      spinal stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are already planning to receive an Transforaminal epidural block from their
      clinician will be approached by study members on the day of their injection. If enrolled, the
      patients will be contacted every 2 weeks for 4 weeks to determine the severity of pain and
      degree of pain relief from the injection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue scale(VAS)</measure>
    <time_frame>12 weeks post - injection</time_frame>
    <description>This is in pain measurement ranging from 0 when no pain to 10 when there is severe pain(low back pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual analogue scale(VAS)</measure>
    <time_frame>4, 8 weeks post - injection</time_frame>
    <description>This is in pain measurement ranging from 0 when no pain to 10 when there is severe pain(low back pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI(Clinicians Global Impression)</measure>
    <time_frame>4, 8 weeks post - injection</time_frame>
    <description>7 point scale that requires the clinician to assess how much the patient's illness has improved(grade 0) or worsened(grade 7) relative to a baseline state at the beginning of the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treadmill test</measure>
    <time_frame>8 weeks post - injection</time_frame>
    <description>walking distance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Spinal Stenosis Lumbar</condition>
  <arm_group>
    <arm_group_label>Polydeoxyribonucleotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polydeoxyribonucleotide(PDRN) 5.625mg/3ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polydeoxyribonucleotide, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polydeoxyribonucleotide(PDRN) 5.625mg/3ml Placebo (Normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Normal saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polydeoxyribonucleotides</intervention_name>
    <description>PDRN injection to epidural space</description>
    <arm_group_label>Polydeoxyribonucleotide</arm_group_label>
    <arm_group_label>Polydeoxyribonucleotide, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Polydeoxyribonucleotide, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Adults aged between 19-80 years old

          -  2. Radiological confirmation of spinal stenosis on MRI

          -  3. Neurogenic claudication greater thanVAS 4 of due to spinal stenosis

          -  4. Follow-up possible during 3 months the clinical trial

        Exclusion Criteria:

          -  Not able to comply fully with the protocol, including treatment, follow-up or study
             procedures

          -  pregnant or feeding women

          -  Alcohol/drug abuse

          -  Anticoagulant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lee pyongbok</last_name>
    <phone>82-2-787-7495</phone>
    <email>painfree@snubh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul national university Bundang hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Kyoung-ki-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunjoo Choi, MD</last_name>
      <phone>82-31-787-6572</phone>
      <email>ejchoi7956@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pyung Bok Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Pyung-Bok Lee</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

